Drug Profile
Afizagabar - Servier
Alternative Names: S-44819Latest Information Update: 09 Aug 2019
Price :
$50
*
At a glance
- Originator Servier
- Class Benzodiazepinones; Oxazoles; Small molecules; Vascular disorder therapies
- Mechanism of Action GABA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 09 Aug 2019 Chemical structure information added
- 29 May 2019 Discontinued - Phase-II for Stroke (In the elderly, In adults) in Canada, Spain, Brazil, France, Italy, Poland, Czech Republic, Netherlands, South Korea, Hungary, Belgium, Germany (PO), United Kingdom, Australia, Sweden (PO) due to negative results from phase II trial
- 04 Apr 2019 Servier completes the phase II EMPOWER BRAIN trial in Stroke in United Kingdom, Sweden, Spain, Poland, Netherlands, Hungary, Germany, Belgium, Australia, France, South Korea, Italy, Canada, Czech Republi and Brazil (NCT02877615)